Tamoxifen Use in Patients with Ductal Carcinoma In Situ and T1a/b N0 Invasive Carcinoma - 21/08/11
, Laura Lazarus, MD , Nanjiang Hou, MS †, Simbi Acharya, MS , Seema A. Khan, MD : FACS, Valerie L. Staradub, MD : FACS, Alfred W. Rademaker, PhD †, Monica Morrow, MD ⁎ : FACS Department of Surgery, Lynn Sage Breast Program, Northwestern University Feinberg School of Medicine, Chicago, IL Correspondence address: Monica Morrow, MD, FACS, Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111-2497.Résumé |
Background |
The purpose of this study was to determine how often patients with ductal carcinoma in situ and T1a/b N0 cancer are offered and accept tamoxifen for secondary chemoprevention.
Study design |
A retrospective review of 284 patients with T1a/b N0 invasive cancer treated between February 1995 and December 2001 and 129 patients with DCIS treated after September 1998 was carried out. Patient and tumor characteristics associated with being offered and accepting tamoxifen were compared.
Results |
Tamoxifen was offered to 67% of the invasive cancer patients and accepted by 76% (51% of the entire group). Hormone receptor status was the only significant predictor of being offered tamoxifen (p = 0.004). Older age (p = 0.04), Caucasian race (p = 0.01), and parity (p = 0.04) in premenopausal women were significant predictors of tamoxifen acceptance on univariate analysis. After the publication of the National Surgical Adjuvant Breast and Bowel Project P-1 trial, significantly more patients were offered tamoxifen (p = 0.02), but acceptance rates did not change. Tamoxifen was offered to 91% of the ductal carcinoma in situ patients and accepted by 73% (67% overall). Lumpectomy was associated with significantly higher rates of being offered (p = 0.02) and accepting tamoxifen (p = 0.002) on univariate analysis.
Conclusions |
Factors associated with tamoxifen risks and benefits correlate poorly with the use of the drug.
Le texte complet de cet article est disponible en PDF.Abbreviations and Acronyms : DCIS, ER, NSABP
Plan
| Competing Interests Declared: None. Supported by Specialized Program of Research Excellence in Breast Cancer P50-CA89018. |
Vol 201 - N° 5
P. 688-694 - novembre 2005 Retour au numéro
Article précédent
- Factors Associated with Insulin and Narcotic Independence after Islet Autotransplantation in Patients with Severe Chronic Pancreatitis
- Syed A. Ahmad, Andrew M. Lowy, Curtis J. Wray, David D’Alessio, Kywran A. Choe, Laura E. James, Andreas Gelrud, Jeffrey B. Matthews, Horacio L.R. Rilo
- Percutaneous Transesophageal Gastrostomy Tube for Decompression of Malignant Obstruction: Report of the First Case and Our Series in the US
- Richard Mackey, Bipan Chand, Hideto Oishi, Shingo Kameoka, Jeffrey L. Ponsky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?